Shares of Intuitive Surgical (ISRG 14.22%) fell this past week on concerns that the robotic surgery leader's growth is slowing.

Image source: Intuitive Surgical.

Solid Q2 results

Intuitive saw a 16% year-over-year rise in worldwide procedures in the second quarter. Procedures with its da Vinci robotic surgical platform rose 15%, while procedures with its Ion robotic-assisted platform for minimally invasive lung biopsies surged 36%.

Intuitive placed 468 da Vinci and 55 Ion systems during the quarter. That contributed to a 12% increase in Intuitive's da Vinci installed base to 11,710 systems and a 21% jump in its Ion installed base to 1,096 systems.

In all, Intuitive's revenue climbed 19% to $2.9 billion, driven by higher system leasing fees and sales of instruments and accessories.

Expand

NASDAQ: ISRG

Intuitive Surgical

Today's Change

(-14.22%) $-57.22

Current Price

$345.11

Key Data Points

Market Cap

$122BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Day's Range

$345.04 - $367.15

52wk Range

$344.55 - $603.88

Volume

604.2K

Avg Vol

2.7M

Gross Margin

71.58%

The robotic technology pioneer's adjusted net income, in turn, grew 25% to $1 billion, or $2.80 per share. That topped Wall Street's estimates, which had called for per-share profits of $2.50.

Intuitive's outlook indicates a slower pace of expansion

Yet investors appeared to focus more on Intuitive's guidance for the second half of 2026.

Management sees worldwide da Vinci procedure growth at the midpoint of its previously issued range of 13.5% to 15.5%. By besting expectations in the second quarter and not raising its full-year guidance, Intuitive is essentially forecasting slower growth for the rest of the year.

Wall Street responded with multiple price target cuts for Intuitive's stock, and many investors decided to sell their shares.